— Know what they know.
Not Investment Advice

IGC AMEX

IGC Pharma, Inc.
1W: -2.7% 1M: -7.1% 3M: -2.2% YTD: -5.5% 1Y: -33.2% 3Y: -23.1% 5Y: -82.0%
$0.27
+0.00 (+1.81%)
 
Weekly Expected Move ±5.9%
$0 $0 $0 $0 $0
AMEX · Healthcare · Biotechnology · Tech Score Sell · Power 32 · $27.5M mcap · 86M float · 0.751% daily turnover · Short 28% of daily vol

Cash Flow Trends

Operating Cash Flow
-$6M -23.9% ▼
Capital Expenditures
$164K +66.0% ▲
5Y CAGR: -36.5%
Free Cash Flow
-$6M -15.7% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$198K +75.0% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2022FY2023FY2024FY2025FY2026
— Operating Activities —
Net Income-$15M-$12M-$13M-$7M-$7M
Depreciation & Amort.$651K$657K$637K$618K$382K
Stock-Based Comp.$2M$3M$2M$2M$452K
Change in Working Capital$3M$794K$2M-$72K$320K
Other Non-Cash Items$2M$616K$3M$140K-$549K
Operating Cash Flow-$7M-$7M-$5M-$5M-$6M
— Investing Activities —
Capital Expenditures-$236K-$619K-$138K-$112K-$709K
Acquisitions (Net)$0$538K$0$0-$21K
Investment Purchases$0-$154K$0$0-$50K
Investment Sales$0-$538K$0$0$0
Other Investing-$506K$538K-$179K-$330K$588K
Investing Cash Flow-$742K-$235K-$317K-$442K-$192K
— Financing Activities —
Net Debt Issuance-$3K-$3K-$3K-$3K$620K
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$0$0$0$0$0
Financing Cash Flow$4M$100K$4M$4M$6M
Net Change in Cash-$4M-$7M-$2M-$793K-$198K
Cash End of Period$10M$3M$1M$405K$207K
Free Cash Flow-$8M-$8M-$6M-$5M-$6M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms